Ingenix Raises €13m From Sofinnova Partners-Led Syndicate to Scale Modality Fusion, a Novel Architecture for Drug Development

Ingenix, a Warsaw-based AI and biology company, has successfully closed a €13 million seed-extension funding round aimed at scaling the development of its innovative Biological Reasoning Engine. The round was led by Sofinnova Partners, with additional participation from Inovo VC and OTB VC. This funding announcement was made on June 3, 2026, and marks a significant milestone for Ingenix as it seeks to enhance its partnerships within the pharmaceutical and biotech sectors.

Ingenix's Biological Reasoning Engine employs a unique architecture known as Modality Fusion, which integrates diverse biological data to generate actionable insights. This approach addresses the complexities of biological systems, which traditional AI models struggle to interpret due to their reliance on larger datasets and general-purpose frameworks. In a recent application, the Engine was able to solve a complex oncology challenge in minutes, delivering results that had previously taken years and substantial financial resources for a partner biotech to achieve. This capability positions Ingenix at the forefront of AI applications in drug development.

The funding will not only facilitate the further development of the Biological Reasoning Engine but also expand Ingenix's Qualified Access Program, which aims to collaborate with select pharma and biotech partners. The program is designed to leverage the Engine's capabilities to address specific research questions, thereby enhancing the efficiency and effectiveness of drug discovery processes. Ingenix's leadership, including CEO Piotr Surma, emphasizes the necessity of an AI architecture tailored specifically for biological applications, rather than a one-size-fits-all solution.

The life sciences sector is witnessing a surge in interest and investment in AI-driven technologies, particularly as companies seek to streamline research and development processes. Ingenix's approach, which combines advanced AI techniques with a deep understanding of biological systems, is indicative of a broader trend towards more specialized and sophisticated tools in drug development. As the demand for faster and more cost-effective solutions grows, Ingenix's innovations could play a crucial role in reshaping the landscape of pharmaceutical research.

In summary, the successful funding round underscores Ingenix's potential to significantly impact the life sciences industry through its advanced AI capabilities. As the company continues to refine its Biological Reasoning Engine and expand its partnerships, it is well-positioned to contribute to the evolution of drug development methodologies. The implications of this funding extend beyond Ingenix, as the life sciences sector increasingly embraces AI technologies to meet the challenges of modern healthcare and research demands.